Skip to content

A study of more time-efficient and cost-effective pre-exposure rabies vaccination schedules to secure timely adequate protection prior to military deployment

A study of more time-efficient and cost-effective pre-exposure rabies vaccination schedules to secure timely adequate protection prior to military deployment - Rabies vaccination study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39883
Enrollment
72
Registered
2013-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: > 18 years of age

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Percentage of vaccinees with RVNA's >0.5 IU/mL. Measurement of Virus neutralizing antibodies: Rabies virus neutralising antibodies (RVNAbs) will be determined in all blood samples by the rapid focus fluorescent inhibition assay (RFFIT), performed in the Erasmus Medical Centre in Rotterdam, the Netherlands. The RFFIT is currently the reference method, prescribed by the WHO. Briefly, a constant dose of previously titrated, cell culture adapted, challenge virus is incubated with serial dilution of the sera to be titrated. A reference serum of known titer is included in each test. The estimation of the percentage of infected cells for each dilution of the sera allows determination of the titer of the unknown sera by comparing with the reference serum. Titers of sera are expressed as International Units per milliliter (IU/ml). Sera with titers *0.5 IU/ml, the WHO recommended protective level, are considered as positive.

Secondary

MeasureTime frame
Adverse events follwong intradermal vaccination

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)